Print E-mail Contact us
Anti-viral Program
Complete service from target valiadation,
assay development and compound screening
MOA study, drug combination study,
compound resistance identification and
charaterizaiton
Genotyping and phenotyping of patient
support clinical virology
A series of in vitro assays are available for HCV, HBV, Influenza virus, RSV, and Herpes
virus (HSV-1, HSV-2, HCMV) to support client Hit ID and Lead discovery effort.
Anti-HCV Assay and Screening
HCV replicon assays (GT1a, 1b or 2a) are available in both 96-well and 384-well format. The infectious system based on GT2a JFH-1, with or without reporter gene, is for compound screening to capture full cycle of HCV replication. HDB also provides customized replicon
construction service for other genotypes with screening supports.
-
Evaluation of effect of drug combination against HCV
-
Generation of drug resistant HCV mutants by cell culture passaging or site-directed mutagenesis
-
Drug resistant mutation identification and profiling
-
Genotyping and phenotyping of viral genes (NS3/NS5A/NS5B) derived from HCV patients
BMS790052 profiling against HCV 2a F28S/Y or Y93H/N mutant replicons
Synergistic effect of two HCV compounds (Figure generated by Macsynergy II)
Anti-HBV Assay and Screening
A primary 96-well/384-well viral DNA qPCR or HBsAg ELISA assay is available in HDB to screen compound inhibiting HBV replication or HBsAg secretion in HepG2.2.15 cell line. Other GT (B/C/D) HBV-expressing cell lines are available for compound screening. HBV infectious system (HepG2-hNTCP or primary human hepatocyte) is also available for
compound efficacy test.
-
Evaluation of drug combination effect against HBV
-
Compound profiling against drug resistant HBV mutants
-
Cytokine stimulation compound screening in PBMC by cytokine multiplexed assay or function assay
HBV compound in combination of TDF or ETV with different drug ratio: combination with TDF shows
slight synergism, combination with ETV shows significant synergism (Figure generated by CompuSyn)
Multiple cytokine quantification by multiplex assay
Virus CPE Assay for Compound Screening
CPE assay (96-well/384-well) is available at HDB for testing compound inhibition of several viruses, including influenza virus A/B, RSV (Respiratory Syncytial Virus), Herpes virus (HSV-1, HSV-2), Enterovirus (EV71 and Coxsackie Virus). Plaque assay is also
available for compound efficacy test.
Influenza virus CPE Assay
HSV-1 plaque reduction assay
Other Services
-
Compound profiling against different influenza virus strains
-
Assay development for mechanism of action of lead compounds
-
Cytotoxicity evaluation of the tested compounds
Tet-inducible HBV-expressing cell line
Contributions to Clients’ Publications
1.
Pickford C., etc: Use of Clinical Samples to Study the Emergence of Resistance to Filibuvir (PF -00868554) and the Potential to Combine with NS5A Inhibitors, Presented at the American Association for the Study of Liver Diseases (AASLD), October 29-
November 2, 2010, Boston, USA
2.
Troke, P., etc: Characterization of Resistance to the Nonnucleoside NS5B Inhibitor Filibuvir in Hepatitis C Virus-Infected Patients, Antimicrobial Agents and Chemotherapy
3.
Christ F., etc, Small-Molecule Inhibitors of the LEDGF/p75 Binding Site of Integrase Block HIV Replication and Modulate Integrase Multimerization, Antimicrobial Agents
and Chemotherapy p. 4365–4374, 2012 (http://dx.doi.org/10.1128/AAC.00717-12)
Related Services
----------------------
----------------------
HD Biosciences (China) Co.,Ltd
590 Ruiqing Road
Zhangjiang East Campus, Pudong, Shanghai 201201,
P.R.China
Tel: +86 (21) 5116 3700
Fax: +86 (21) 5116 3766
info@hdbiosciences.com
SERVICES
|
THERAPEUTIC AREAS
|
NEWS & EVENTS